Arginase as a mediator of diabetic retinopathy

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  Patel, Chintan ^a   Rojas, Modesto ^a   Narayanan, S Priya ^a   Zhang, Wenbo ^a,c   Xu, Zhimin ^a   Lemtalsi, Tahira ^a   Jittiporn, Kanjana ^a   Caldwell, R William ^a   Caldwell, Ruth B ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Arginase; Diabetes; Diabetic retinopathy; High glucose; Nitric oxide; Oxidative stress

Indexed keywords

2(S) AMINO 6 BORONOHEXANOIC ACID; 3 NITROTYROSINE; 4, 5 DIAMINOFLUORESCEIN DIACETATE; ARGINASE; ARGINASE 1; ENZYME INHIBITOR; GLUCOSE; HYDROETHIDINE; INTERCELLULAR ADHESION MOLECULE 1; ISOENZYME; N (G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE; NITRITE; OXYGEN; PEROXYNITRITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CELL DEATH; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; IMMUNOFLUORESCENCE MICROSCOPY; LEUKOCYTE ADHERENCE; LEUKOSTASIS; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; VASODILATATION; WESTERN BLOTTING;

EID: 84883240293     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00173     Document Type: Article

References (55)

1. NEI. The Prevalence of Diabetic Retinopathy Among Adults in the United States (2008). Available from: http://www.nei.nih.gov/eyedata/pbd3.asp
2. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol (2002) 47(Suppl 2):S253-62. doi:10.1016/S0039-6257(02)00387-9
3. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res (2011) 30(5):343-58. doi:10.1016/j.preteyeres.2011.05.002
4. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl (2000) 77:S26-30. doi:10.1046/j.1523-1755.2000.07705.x
5. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes (2001) 50(7):1636-42. doi:10.2337/diabetes.50.7.1636
6. Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem (2002) 80(5):771-9. doi:10.1046/j.0022-3042.2001.00737.x
7. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care (2003) 26(5):1589-96. doi:10.2337/diacare.26.5.1589
8. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB, et al. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol (2003) 162(6):1995-2004. doi:10.1016/S0002-9440(10)64332-5
9. Takeda M, Mori F, Yoshida A, Takamiya A, Nakagomi S, Sato E, et al. Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats. Diabetologia (2001) 44(8):1043-50. doi:10.1007/s001250100588
10. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci (2003) 44(7):3135-43. doi:10.1167/iovs.02-1022
11. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrósio AF, et al. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood -retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci (2007) 48(11):5257-65. doi:10.1167/iovs.07-0112
12. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, et al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia (2007) 50(9):1987-96. doi:10.1007/s00125-007-0772-3
13. Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res (2007) 26(3):205-38. doi:10.1016/j.preteyeres.2007.01.004
14. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis (1995) 38(2):87-104. doi:10.1016/S0033-0620(05)80001-5
15. Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol (1995) 25 (3):397-403. doi:10.1097/00005344-199503000-00008
16. Angulo J, Rodriguez-Manas L, Peiró C, Neira M, Marín J, Sánchez-Ferrer CF. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol (1998) 358(5):529-37. doi:10.1007/PL00005289
17. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest (1992) 90 (3):1168-72. doi:10.1172/JCI115937
18. Tarry WC, Makhoul RG. L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb (1994) 14(6):938-43. doi:10.1161/01.ATV.14.6.938
19. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res (2008) 102(1):95-102. doi:10.1161/CIRCRESAHA.107.155028
20. Romero MJ, Iddings JA, Platt DH, Ali MI, Cederbaum SD, Stepp DW, et al. Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol (2012) 302(1):H159-66. doi:10.1152/ajpheart.00774.2011
21. Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, Verin AD, et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol (2011) 300(5):C1181-92. doi:10.1152/ajpcell.00328.2010
22. Zhang W, Baban B, Rojas M, Tofigh S, Virmani SK, Patel C, et al. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol (2009) 175(2):891-902. doi:10.2353/ajpath.2009.081115
23. Elms SC, Toque HA, Rojas M, Xu Z, Caldwell RW, Caldwell RB. The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia (2013) 56(3):654-62. doi:10.1007/s00125-012-2789-5
24. Deignan JL, Livesay JC, Yoo PK, Goodman SI, O'Brien WE, Iyer RK, et al. Ornithine deficiency in the arginase double knockout mouse. Mol Genet Metab (2006) 89(1-2):87-96. doi:10.1016/j.ymgme.2006.04.007
25. Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol (2005) 167(2):599-607. doi:10.1016/S0002-9440(10)63001-5
26. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, et al. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci (2008) 49(7):3239-44. doi:10.1167/iovs.08-1755
27. Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med (2000) 28(1):91-101. doi:10.1016/S0891-5849(99)00216-6
28. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C - dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes (2000) 49(11):1939-45. doi:10.2337/diabetes.49.11.1939
29. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res (2001) 88 (2):E14-22. doi:10.1161/01.RES.88.2.e14
30. Lefer AM. Nitric oxide: nature's naturally occurring leukocyte inhibitor. Circulation (1997) 95(3):553-4. doi:10.1161/01.CIR.95.3.553
31. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation (2003) 108(16):2000-6. doi:10.1161/01.CIR.0000092948.04444.C7
32. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J (2003) 17(15):2328-30.
33. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension (2004) 44(6):935-43. doi:10.1161/01.HYP.0000146907.82869.f2
34. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol (2007) 34(9):906-11. doi:10.1111/j.1440-1681.2007.04638.x
35. Clermont AC, Bursell SE. Retinal blood flow in diabetes. Microcirculation (2007) 14(1):49-61. doi:10.1080/10739680601072164
36. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res (2007) 2007:43603. doi:10.1155/2007/43603
37. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol (2008) 30(2):65-84. doi:10.1007/s00281-008-0111-x
38. Mishra A, Newman EA. Aminoguanidine reverses the loss of functional hyperemia in a rat model of diabetic retinopathy. Front Neuroenergetics (2011) 3:10. doi:10.3389/fnene.2011.00010
39. Chen B, Keshive M, Deen WM. Diffusion and reaction of nitric oxide in suspension cell cultures. Biophys J (1998) 75(2):745-54. doi:10.1016/S0006-3495(98) 77564-2
40. Hagenfeldt L, Dahlquist G, Persson B. Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr Scand (1989) 78 (2):278-82. doi:10.1111/j.1651-2227.1989.tb11070.x
41. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther (1997) 283(2):684-91.
42. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun (2001) 283(4):923-7. doi:10.1006/bbrc.2001.4874
43. Jiang M, Jia L, Jiang W, Hu X, Zhou H, Gao X, et al. Protein disregulation in red blood cell membranes of type 2 diabetic patients. Biochem Biophys Res Commun (2003) 309(1):196-200. doi:10.1016/S0006-291X(03)01559-6
44. White AR, Ryoo S, Li D, Champion HC, Steppan J, Wang D, et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension (2006) 47(2):245-51. doi:10.1161/01.HYP.0000198543.34502.d7
45. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res (2008) 102 (8):923-32. doi:10.1161/CIRCRESAHA.107.169573
46. Narayanan SP, Suwanpradid J, Saul A, Xu Z, Still A, Caldwell RW, et al. Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS One (2011) 6(7):e22460. doi:10.1371/journal.pone.0022460
47. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 2(8567):1057-8. doi:10.1016/S0140-6736(87)91481-4
48. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A (1991) 88(11):4651-5. doi:10.1073/pnas.88.11.4651
49. Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry (2001) 40(6):1688-93. doi:10.1021/bi002239y
50. Baker PR, Schopfer FJ, O'Donnell VB, Freeman BA. Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. Free Radic Biol Med (2009) 46(8):989-1003.
51. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (2009) 107(4):1249-57. doi:10.1152/japplphysiol.91393.2008
52. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation (2004) 109(14):1729-34. doi:10.1161/01.CIR.0000124718.99562.91
53. Dunn J, Gutbrod S, Webb A, Pak A, Jandu SK, Bhunia A, et al. S-nitrosation of arginase 1 requires direct interaction with inducible nitric oxide synthase. Mol Cell Biochem (2011) 355(1-2):83-9. doi:10.1007/s11010-011-0841-2
54. Thengchaisri N, Hein TW, Wang W, Xu X, Li Z, Fossum TW, et al. Upregulation of arginase by H2O2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol (2006) 26(9):2035-42. doi:10.1161/01.ATV.0000233334.24805.62
55. Chandra S, Romero MJ, Shatanawi A, Alkilany AM, Caldwell RB, Caldwell RW. Oxidative species increase arginase activity in endothelial cells through RhoA/Rho kinase pathway. Br J Pharmacol (2012) 156:506-19. doi:10.1111/j.1476-5381.2011.01584.x